BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24720363)

  • 1. Metabolic features of melanoma: a gold mine of new therapeutic targets?
    Marchetti P; Guerreschi P; Kluza J; Mortier L
    Curr Cancer Drug Targets; 2014; 14(4):357-70. PubMed ID: 24720363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming melanoma drug resistance through metabolic targeting?
    Smalley KS
    Pigment Cell Melanoma Res; 2013 Nov; 26(6):793-5. PubMed ID: 24152044
    [No Abstract]   [Full Text] [Related]  

  • 3. Melanoma epigenetics: novel mechanisms, markers, and medicines.
    Lee JJ; Murphy GF; Lian CG
    Lab Invest; 2014 Aug; 94(8):822-38. PubMed ID: 24978641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in targeted therapy for unresectable melanoma: new drugs and combinations.
    Hao M; Song F; Du X; Wang G; Yang Y; Chen K; Yang J
    Cancer Lett; 2015 Apr; 359(1):1-8. PubMed ID: 25578781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding melanoma signaling networks as the basis for molecular targeted therapy.
    Smalley KS
    J Invest Dermatol; 2010 Jan; 130(1):28-37. PubMed ID: 19571822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
    Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
    Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drug targets in metastatic melanoma.
    Homet B; Ribas A
    J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK inhibitors for the treatment of NRAS mutant melanoma.
    Sarkisian S; Davar D
    Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of pyrrolobenzodiazepine-gallic hybrid agents as p53-dependent and -independent apoptogenic signaling in melanoma cells.
    Chou YW; Senadi GC; Chen CY; Kuo KK; Lin YT; Wang JJ; Lee JH; Wang YC; Hu WP
    Eur J Med Chem; 2016 Feb; 109():59-74. PubMed ID: 26756315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab success in untreated metastatic melanoma.
    Wilkinson E
    Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
    [No Abstract]   [Full Text] [Related]  

  • 11. RASopathic alopecia: hair changes associated with vemurafenib therapy.
    Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
    J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
    [No Abstract]   [Full Text] [Related]  

  • 12. Mitogen-Activated Protein Kinase Signaling Pathway in Cutaneous Melanoma: An Updated Review.
    Acosta AM; Kadkol SS
    Arch Pathol Lab Med; 2016 Nov; 140(11):1290-1296. PubMed ID: 27788045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular alterations in melanoma and targeted therapies].
    Mourah S; Lebbé C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S5-S11. PubMed ID: 25776766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression.
    Chaube B; Malvi P; Singh SV; Mohammad N; Meena AS; Bhat MK
    Oncotarget; 2015 Nov; 6(35):37281-99. PubMed ID: 26484566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targeted therapies in melanoma.
    Kudchadkar RR; Gonzalez R; Lewis K
    Cancer Control; 2013 Oct; 20(4):282-8. PubMed ID: 24077404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma in 2013: Melanoma--the run of success continues.
    Schadendorf D; Hauschild A
    Nat Rev Clin Oncol; 2014 Feb; 11(2):75-6. PubMed ID: 24419300
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting invasive properties of melanoma cells.
    Arozarena I; Wellbrock C
    FEBS J; 2017 Jul; 284(14):2148-2162. PubMed ID: 28196297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Update on BRAF and MEK inhibitors in the treatment of malignant melanoma].
    Gutzmer R
    J Dtsch Dermatol Ges; 2015 May; 13(5):485-7. PubMed ID: 25918105
    [No Abstract]   [Full Text] [Related]  

  • 19. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma.
    Verduzco D; Flaherty KT; Smalley KS
    Exp Dermatol; 2015 Sep; 24(9):657-8. PubMed ID: 26010519
    [No Abstract]   [Full Text] [Related]  

  • 20. Energy metabolism in skin cancers: A therapeutic perspective.
    Hosseini M; Kasraian Z; Rezvani HR
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):712-722. PubMed ID: 28161328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.